Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Syros Pharmaceuticals ( (SYRS) ) has shared an announcement.
Syros Pharmaceuticals faces significant challenges as it terminates its collaboration with QIAGEN, following the failure of its SELECT-MDS-1 Phase 3 trial to meet key endpoints. This resulted in a default under its Loan Agreement with Oxford Finance, demanding nearly $43.7 million repayment. In response, Syros has initiated a drastic workforce reduction of 94% to curb costs and maximize stakeholder value, highlighting its ongoing financial struggles.
See more insights into SYRS stock on TipRanks’ Stock Analysis page.
Trending Articles
- Shareholder Alert for iLearningEngines Holdings (NASDAQ:AILE)
- 3 Penny Stocks to Watch Now, 11/19/24
- Class Action Lawsuit Against Metagenomi Inc. (NASDAQ:MGX)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
